MedTrace Logo

Daily Chlorexidine Bath for Health Care Associated Infection Prevention

NCT05485051 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15730

Last updated 2024-06-13

No results posted yet for this study

Summary

Cluster randomized controlled trial comparing two bathing strategies in critically ill patients. The intervention group will receive daily bathing with chlorhexidine. The control group will receive usual care.

Conditions

  • Health Care Associated Infection
  • Ventilator Associated Pneumonia
  • Central Line-associated Bloodstream Infection (CLABSI)
  • Catheter-Associated Urinary Tract Infection

Interventions

OTHER

2% chlorhexidine digluconate solution with surface-active agents

Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.

OTHER

Usual Baths

Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.

Sponsors & Collaborators

  • Hospital Sírio-Libanês

    collaborator UNKNOWN

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • Hospital Moinhos de Vento

    collaborator OTHER

  • Hospital Alemão Oswaldo Cruz

    collaborator OTHER

  • A Beneficência Portuguesa de São Paulo

    collaborator UNKNOWN

  • Hospital do Coracao

    lead OTHER

Principal Investigators

  • Bruno M Tomazini, M.D · [email protected]

  • Alexandre B Cavalcanti, M.D · HCor Research Institute Director

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485051 on ClinicalTrials.gov